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Summary
Mana-Hox, an analog of b-carbolines with anticancer
activity, induces aberrant mitosis and delays mitotic
exit. However, the cellular target is not known. In this
study, we visualized the intracellular localization of
Mana-Hox. Mana-Hox rapidly penetrated into cells
(within 1min) and concentrated on disorganizedmeta-
phase chromosomes after 13 hr of exposure. We dem-
onstrated that Mana-Hox is a noncovalent DNA binder
that can interact with DNA through intercalation and/or
through minor groove binding. Furthermore, Mana-
Hox also inhibits topoisomerase II relaxation activity
in vitro, suggesting that Mana-Hox could perturb mi-
totic chromosome decatenation. Overall, Mana-Hox
binding to DNA plays a critical role in the induction
of aberrant mitosis and contributes to its anticancer
activity.
Introduction
Anticancer drugs interrupt mitosis by targeting the mi-
totic apparatus or chromosomes [1, 2]. The perturbation
of mitotic apparatus by antimicrotubule drugs such as
taxol and vinca alkaloids block the cell cycle at mitosis
[3]. Unlike antimicrotubule drugs, drugs such as cis-
platin and doxorubicin disrupt chromosome integrity
and usually block cells’ entry into mitosis [4]. However,
whether the cell cycle can be blocked before mitosis fol-
lowing DNA damage may depend on whether cells can
detect changes or damages on chromosome DNA [5–7].
Whether DNA damaging or binding agents induce sig-
nificant changes on DNA can depend on their interaction
with DNA. DNA binding agents can bind to DNA by either
covalent or noncovalent interaction [8]. Covalent bind-
*Correspondence: fyeh@ym.edu.tw
5 Present address: The Institute for Systems Biology, Seattle,
Washington 98103.ing agents such as cisplatin directly induce lesions on
the DNA template, while noncovalent binding agents
such as ethidium bromide and benzimidazole do not.
It is known that noncovalent interactions rely on the
strength of electrostatic interactions, i.e., hydrogen bond-
ing and van der Waals interactions. Such interactions
cannot produce stable drug-DNA complexes [8, 9], and
they, therefore, do not significantly damage DNA unless
DNA enzymes such as topoisomerase intervene [9].
Noncovalent DNA binding can alter chromatin structure
by unwinding the DNA helix or widening the minor
groove [10–12]. Since endogenous DNA binding pro-
teins such as TBP also alter DNA structure [13, 14], it
is not known if cells would be aware of similar changes
induced by a noncovalent DNA binding agent.
Noncovalent DNA binding agents often possess
structural characteristics such as planar aromatic ring
systems and basic side chains [8, 9]. Many natural prod-
ucts and their derivatives, such as anthracyclines, pyri-
docarbazoles, and b-carboline alkaloids, also possess
such structural characteristics and can intercalate or
bind to the DNA minor groove [15, 16]. Our previous
study identified a synthetic analog of b-carboline Mana-
Hox [17] 1 (Figure 1). It is composed of a b-carboline and
a carbazole chromophore and exhibits anticancer activ-
ity on several human cancer cell lines [18]. 1 induces
cancer cell death by interfering with mitosis. After cells
are treated with 1, many aberrant mitotic cells, including
those with bipolar spindles and lagged chromosomes
and those with multipolar spindles and disorganized
chromosomes, appear and are accompanied by the ac-
tivation of the spindle checkpoint that delayed cell exit
from mitosis. The aberrant mitotic cells eventually exit
mitosis, resulting in chromosome missegregation and
cell death. However, 1 is not an antimicrotubule agent.
The impairment of mitosis by 1 does not result from
the inhibition of microtubules.
In this study, we examined the DNA binding activity of
1 in intact cells and in a cell-free system. We demon-
strated that 1 both binds and intercalates in the DNA mi-
nor groove. The binding of 1 to chromosomal DNA plays
a critical role in its induction of aberrant mitosis.
Results
Mana-Hox Binds to Nuclear DNA
1 exhibits absorption in both the near-UV region and
the visible region. Two absorption bands, centered at
287 nm and 350 nm, are known to be associated with
the carboline moiety. Another absorption band, centered
at 414 nm, is caused by the carbazole moiety (data not
shown). We took advantage of its absorption property
to visualize the localization of 1 in live cells. HeLa cells
were treated with 4 mM 1 and observed directly by a fluo-
rescence microscope under UV excitation. As shown in
Figure 2A, fluorescent signals of 1 were detected inside
the cell after 1 min of drug exposure as punctuate spots
that gradually concentrated around the nuclear envelope
(10 min and 60 min). After 5 hr, the fluorescence of 1was
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1318found in the nucleus (double arrows) and the nucleolus
(double arrowheads).
The fluorescent signals of 1 progressively accumu-
lated in the area next to the nucleus that corresponded
to the Golgi apparatus (Figure 2A, arrows), endoplasmic
reticulum (ER), and mitochondria (Figure 2A, arrow-
heads, 60 min panel). To test if 1 distributes in these sub-
cellular compartments, HeLa cells were transfected
with probes specific for the Golgi, ER, and mitochondria
as described in Experimental Procedures. Cells were
treated with 1 at 12 hr posttransfection. As shown in
Figure 2B, 1 accumulated mainly in the Golgi complexes
(arrows) at 1 min of exposure. After 60 min, 1 appeared in
the reticulum or rod-shaped organelles (arrowheads),
including ER (Figure 2C) and mitochondria (Figure 2D).
1 is known to induce aberrant mitosis [18]. To deter-
mine whether 1 binds to abnormal metaphase chromo-
somes, HeLa cells were treated with 1 for 13 hr and
observed by fluorescence microscope. As shown in Fig-
ure 2E, the fluorescence of 1 appeared in lagged chro-
mosomes (a and b, arrows), Y-shaped chromosomes
(c, dashed line), and other disorganized chromosomes
(d). Cells that were then stained with the DNA dye
Hoechst 33258 further demonstrated that 1 colocalized
with chromosome DNA (Figure 2F).
Mana-Hox Directly Binds to DNA
To test if 1 directly binds to DNA, fluorescence emission
spectra were measured with an excitation wavelength of
287 nm. The binding of 1 to DNA was characterized by a
decrease of the fluorescence intensity (hypochromicity)
between 350 and 375 nm until a DNA/drug (P/D) ratio of
2.5 was reached (Figure 3). In contrast, fluorescence in-
tensity was increased (hyperchromicity) between 495
and 520 nm with a wavelength shift of about 5–20 nm de-
pending on DNA concentration, indicating that the bind-
ing of DNA altered the geometry of 1. Similar results
were also obtained when the excitation wavelength was
set at 350 and 414 nm (data not shown). Scatchard plots
were made based on the fluorescence data obtained at
372 and 520 nm and were fitted into a two-site model
[19]. This resulted in the determination of two binding
sites, n1 = 1.56 0.06 and n2 = 2.76 0.01, with two bind-
ing constants, K1 = 6.5 6 0.3 3 10
6 M21 and K2 = 1.6 6
0.1 3 106 M21, respectively. These fluorescence mea-
surements indicate that 1 binds to DNA.
Mana-Hox Quenches the Fluorescence
of Ethidium Bromide-DNA Complexes
Hypochromicity is known to be associated with many
DNA intercalators [20, 21]. To test if 1 would intercalate
DNA, we utilized the ethidium bromide displacement as-
say, in which another intercalating agent would reduce
the fluorescence intensity caused by ethidium bromide-
DNA complexes. Calf thymus DNA was incubated with
Figure 1. Structure of Mana-Hox and Analogsethidium bromide and 1 in various proportions. The al-
teration of fluorescence was measured with a fluorome-
ter. As shown in Figure 4A, the addition of 1 reduced the
fluorescence of ethidium bromide-DNA in a concentra-
tion-dependent manner. The C50 value was 10 mM. By
contrast, the other analogs, 2 and 3, showed no effect
on the fluorescence intensity of ethidium bromide-DNA.
Mana-Hox Causes Mobility Retardation
of Supercoiled DNA
To further examine the interaction between 1 and DNA,
we observed the mobility of supercoiled DNA on aga-
rose gels in the presence or absence of 1. As shown in
Figure 2. Cellular Localization of Mana-Hox in HeLa Cells
(A) HeLa cells were exposed to 4 mM 1 for 1 min, 10 min, 60 min, or
5 hr. After drug removal, cells were observed with a fluorescence
microscope, and the presence and distribution of 1were determined
by its fluorescence.
(B–D) HeLa cells were transfected with organelle markers as de-
scribed in Experimental Procedures. Cells were treated with 1 for
the indicated time at 12 hr posttransfection. The colocalization of 1
and the subcellular organelles were examined with a fluorescence
microscopy.
(E) HeLa cells were exposed to 4 mM Mana-Hox for 13 hr. After drug
removal, cells were observed with a fluorescence microscope. Note
the accumulation of 1 in the aberrant metaphase chromosomes.
(F) Drug treatments were as described in (E). The presence of Mana-
Hox (stainedgreen) in theaberrantmetaphasechromosomeswascon-
firmed by the staining with the DNA dye Hoechst 33258 (stained blue).
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was retarded in the presence of 1 in a concentration-
dependent manner (lane 1 and lanes 3–9). At a concen-
tration of 50 mM and above, the 1-induced mobility shift
reached a plateau. Ethidium bromide (lane 2) is known to
relax superhelical DNA and induce a significant mobility
shift. Another drug, taxol, which is not known to bind to
DNA, did not induce a plasmid DNA mobility shift, and it
served as a negative control (lane 10). Similar results
were obtained when this experiment was performed
with a linear DNA marker (data not shown; Figure S1).
Mana-Hox Quenches the Fluorescence
of Hoechst-DNA Complexes
Hyperchromicity is a characteristic of many DNA minor
groove binders. To test if 1 is a DNA minor groove binder,
a competition titration with Hoechst 33258 was per-
formed. Calf thymus DNA was incubated with Hoechst
33258 and1 in various proportions. The alteration of fluo-
rescence was measured with a fluorometer. As shown in
Figure 4C, the addition of 1 reduced the fluorescence in-
tensity of Hoechst-DNA in a concentration-dependent
manner. The C50 value was 2.5 mM. By contrast, the other
analogs, 2 and 3, showed no effect on the fluorescence
intensity.
Mana-Hox Can Bind to DNA through Intercalation
and the Minor Groove
To predict a possible binding mode of 1 and DNA,
a docking study was conducted by using the AutoDock
program [22, 23]. The reference DNA double helix co-
ordinate used for docking was a B form duplex DNA,
50-d(CCGGCGGT)-30. As shown in Figure 5A, the indolyl
moiety of the carboline skeleton intercalated between
GC base pairs and formed hydrogen bonds via a water-
mediated interaction (Figure 5A, c), and it placed the car-
bazole moiety in the minor groove. The docking energy
was 212.36 kcal/mol (Table 1). Analog 2 does not have
Figure 3. Fluorescence Spectrum of Mana-Hox and Its Alteration
upon the Addition of DNA
Solutions were excited at 287 nm, and emission spectra were re-
corded. Solutions consist of 1 mM 1 (D) and calf thymus DNA (P)
at 0.25, 0.5, 1, 2.5, 5, 7.5, and 10 mM.Figure 4. Mana-Hox Can Intercalate DNA and Bind to the DNA Mi-
nor Groove
(A) Quenching of fluorescence intensity of the ethidium bromide-
DNA complex by Mana-Hox and analogs. Calf thymus DNA (20 mM)
was preincubated with 2 mM ethidium bromide in 0.01 M ionic
strength buffer, and was then incubated separately with 1, 2, and 3
in various concentrations for another 10 min. The samples were ex-
cited at 538 nm, and the fluorescence was measured at 590 nm
(mean 6 SEM; n = 3).
(B) Effect of Mana-Hox on the electrophoretic mobility of supercoiled
DNA. pC86 (2 mg) was preincubated with various concentrations of 1
for 30 min, loading buffer was then added, and the samples were
electrophoresed through 1% agarose gels. Abbreviations: S, plas-
mid DNA; EB, ethidium bromide; Tx, taxol; OC, nicked, open circular
DNA; SC, supercoiled DNA.
(C) Quenching of fluorescence intensity of the Hoechst 33258-DNA
complex by Mana-Hox and analogs. Calf thymus DNA (1 mg) was pre-
incubated with 6.1 mM Hoechst 33258 in PBS for 10 min at room tem-
perature, and was then incubated separately with 1, 2, and 3 in vari-
ous concentrations for another 10 min. The samples were excited at
355 nm, and the fluorescence was measured at 460 nm (mean 6
SEM; n = 3).
Chemistry & Biology
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experienced a gain in docking energy of 0.6 kcal/mol
(211.76 versus 212.36 kcal/mol) (Table 1 and Fig-
ure S2A). In analog 3, a nitrophenyl group replaces the
carbazole moiety and exists in R and S configurations.
These two stereoisomers were docked separately into
the intercalation site. The lowest docking energy was
26.33 and 25.39 kcal/mol for R and S isomers (Table 1
and Figure S2A), respectively.
1 was also docked into another reference DNA double
helix,aDNAdodecamer,d(CGCAAATTTCGCG)2, incom-
plex with the minor groove binder Hoechst 33258 (PDB
code: 264d). The suggested minor groove binding
mode is shown in Figure 5B. 1 adopts a conformation
with a dihedral angle of 31º between the b-carboline
and carbazole rings, enabling it to fit well in the minor
groove. The b-carboline NH of 1 is hydrogen bonded to
the O-2 atom of thymidine designated T19. The N-ethyl
Figure 5. The Energy-Minimized Docked Model of the Mana-Hox-
DNA Complex
(A) The lowest-energy docked conformations proposed the ener-
getically favorable binding of 1, with the b-carboline moiety being
intercalated into d(CCGGCGGT)2. a, line plot; b, space-filling plot.
c, hydrogen bonding interactions in the intercalation site of the
energy-minimized docked model of the 1-DNA complex. The water
molecule was from the solvation calculations.
(B) The lowest-energy docked conformations proposed the energet-
ically favorable binding of 1 to d(CGCAAATTTGCG)2 through the
minor groove. a, line plot; b, space-filling plot. The following color
scheme is used: 1: carbon, green; nitrogen, blue; hydrogen, white;
hydrogen bond, white dotted line; oxygen, red; DNA duplex, purple.group of 1 is deeply inserted into the groove to where it
interacts with DNA via van der Waals forces. The docking
energy was 212.6 kcal/mol (Table 1).
In comparison with 1, the lowest docking energy of 2
was determined to be 211.33 kcal/mol (Table 1, Model
I of 2; Figure S3B), indicating that no intermolecular hy-
drogen bond is formed by the NH group of 2. When 2
adopts a docking orientation similar to that of 1, the re-
sulting docking energy of the 2-DNA complex (Model II
of 2) is less stable by 1.67 kcal/mol (210.93 versus
212.6 kcal/mol) due to the lack of the N-ethyl group.
Analogs 3R and 3S were docked differently into the mi-
nor groove. The lowest docking energy was 26.49 and
27.68 kcal/mol for the R and S isomers (Table 1 and
Figure S3C), respectively.
Mana-Hox Inhibits Topoisomerase II
Relaxation Activity
It is known that many minor groove binders can also in-
hibit topoisomerase activity [24, 25]. The effect of 1 on
topoisomerase II (topo II) activity was determined by
measuring the relaxation of plasmid DNA. Supercoiled
plasmid DNA (Figure 6, lane 1) was completely relaxed
in the presence of topo II (lane 2) and partially relaxed
in the presence of etoposide (lane 3), which is a known
topo II inhibitor. 1 at concentrations less than 50 mM
did not inhibit topo II relaxation of supercoiled DNA
(lanes 6–9), but, at 50 and 100 mM, the relaxation was
substantially inhibited (lanes 4 and 5). The mobility shift
of supercoiled DNA in the presence of 50 and 100 mM 1
might also result from DNA intercalation (lanes 4 and 5).
Discussion
Induction of aberrant mitosis has been found in many
antimicrotubule agent-treated cells. Since antimicrotu-
bule agents can modify microtubule behavior and impair
spindle fiber formation, the subsequent activation of
spindle assembly checkpoints prevents cell exit from
mitosis, causing the appearance of abnormal mitotic
cells such as monopolar and multipolar mitotic cells,
and resulting in chromosome missegregation. Our pre-
vious study found a novel anticancer agent 1, which
also delays cell exit from mitosis and causes aberrant
Table 1. Docking Energies of Compounds 1–3 Docked into DNA
with the AutoDock 3.0 Program
Compound Docking Site
Docking Energy
(kcal/mol)a
1 (Mana-Hox) Intercalation cavity 212.36
2 Intercalation cavity 211.76
3 (R isomer) Intercalation cavity 26.33
3 (S isomer) Intercalation cavity 25.39
1 (Mana-Hox) Minor groove 212.60
2 (Model I) Minor groove 211.33
2 (Model II) Minor groove 210.93
3 (R isomer) Minor groove 26.49
3 (S isomer) Minor groove 27.68
1 (Mana-Hox) Major groove 28.98
The energy calculations were performed by using the AutoDock 3.0
energy scoring function.
a The value is the lowest docking energy for each compound, with
the exception of 2 (Model II).
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study, we demonstrated that 1-induced aberrant mitosis
is a result of noncovalent DNA binding.
Based on live cell images, 1 rapidly penetrated the cell
membrane and distributed to membranous organelles,
but it was not detectable in interphase nuclei until 5 hr
posttreatment (Figure 2). 1 was minimally detectable
in interphase nuclei (Figure 2A, 5 hr), possibly because
a large percentage of 1was retained in the membranous
organelles and/or the fluorescence was easily quenched
on noncondensed chromosomes. When 1 induced sig-
nificant numbers of cells to arrest in metaphase (13 hr),
the fluorescence of 1 appeared on the mispositioned
chromosomes and colocalized with Hoechst staining
(Figures 2E and 2F), indicating that 1 is in contact with
DNA. Our other study with fluorescence lifetime mea-
surements (Shiao and C.-H.L., unpublished data) also
supports the idea that 1 binds to nuclear DNA. These re-
sults raised the question as to how a DNA binding agent
can induce mitosis arrest without slowing down S phase
progression. In general, drugs that bind to DNA can in-
troduce lesions on the DNA template and block DNA
replication. In response to DNA binding/damaging
agents, cells can activate DNA damage checkpoints to
prevent entry into mitosis with damaged DNA or incom-
pletely replicated DNA [26]. However, 1 does not impede
cell cycle progression through S phase [18], suggesting
that the binding of 1 to DNA might not induce DNA dam-
age. The binding of 1 to DNA apparently influences the
alignment of chromosomes on spindle fibers, indicating
that 1 might alter DNA structure and interfere with DNA
binding proteins that are required for chromosome seg-
regation [27].
The influences of 1 on DNA can be explained by its in-
teraction with DNA in vitro. The addition of DNA to 1
caused two significant alterations to the fluorescence
emission spectrum. The hypochromicity effect (Figure 3)
is also found to be associated with several classical DNA
intercalators such as ethidium bromide, cryptolepine,
matadine, and acridine [20, 21], suggesting that 1 exhib-
its DNA intercalation activity. Consistent with this obser-
vation, 1 displaced ethidium bromide from DNA, result-
Figure 6. Mana-Hox Inhibits Topoisomerase II Relaxation
Plasmid DNA (1 mg) was incubated with various concentrations of 1,
and was then treated with 8 U topoisomerase II for 30 min at 37ºC.
The reaction was stopped by adding EDTA/SDS. The samples were
electrophoresed through 1% agarose gel. S, supercoiled DNA;
T, topoisomerase II; E, etoposide (85 mM).ing in the decrease of the fluorescence of ethidium
bromide-DNA complexes (Figure 4A). The binding con-
stant Ka calculated from this assay was 2.44 3 10
6 M21,
which is close to the K2 calculated from a fluorescence
emission spectrum. In addition, 1 also retarded linear
marker DNA (data not shown and Figure S1) and super-
coiled plamid DNA migration during agarose gel electro-
phorsis (Figure 4B), further demonstrating that 1 can in-
tercalate with DNA.
The hyperchromicity and red shift effect (Figure 3)
have been found in DNA minor groove binders such as
Hoechst 33258 [10], suggesting that 1 can also bind to
DNA through minor groove interaction. In agreement
with this observation, 1 quenched the fluorescence in-
duced by Hoechst-DNA complexes (Figure 4C). The Ka
value was 5.8 3 106 M21, which is close to the K1 value
calculated from a fluorescence emission spectrum. Of
note, the C50 values of 1 in the reduction of Hoechst-
DNA complex fluorescence was 4-fold lower than
that for ethidium bromide-DNA complexes (Figures 4A
and 4C). It is also known that the C50 value of an inter-
calator in the ethidium bromide displacement assay is
usually higher than 20 mM. The C50 value of 1 is less
than 15 mM, indicating that it preferentially binds to
DNA through interaction with the minor groove [28, 29].
Furthermore, based on chemical structure, 1 contains
a 3,4-dihydropyridoindole (dihydro b-carboline) and an
N-ethylcarbazole [17]. Chemicals containing one of
these chromophores are known DNA intercalators [9].
However, unlike other simple b-carboline alkaloids such
as harman and norharman [30], our results revealed
that 1 can intercalate DNA and also bind to the DNA mi-
nor groove.
When 1 was docked into a GC-rich B form of DNA,
only the indole part of the b-carboline moiety inserted
into the GC base pairs, unlike simple b-carboline alka-
loids or carbazole derivatives of which the planar chro-
mophore intercalates between nitrogen base pairs. It
is known that the planar aromatic ring systems stack
with the DNA base pairs, and that this interaction is im-
portant for DNA intercalation. However, 1 is a dihydro
b-carboline in which the conformation of dihydro pyri-
dine hampers the planar surface and impedes 1 stacking
with DNA base pairs with its entire b-carboline moiety
(Figure 5A). Since there is only one single bond distance
between the dihydro b-carboline and the carbazole moi-
ety, 1 cannot intercalate DNA like a bis-intercalator.
Rather, the angle between the dihydro b-carboline and
the carbazole moiety results in the carbazole moiety
hanging over the DNA minor groove. This result sup-
ports the indication that 1may be a nonclassical DNA in-
tercalator, which partially stacks with DNA base pairs
[16, 31] and partially occupies the DNA minor groove.
Like many DNA minor groove binders, 1 is composed
of two heteroaromatic rings linked together directly
through a single bond [16, 32]. When 1 was docked into
the DNA minor groove, 1 adopted a conformation similar
to that of Hoechst 33258 and formed a stable complex in
the DNA minor groove. However, 1 can only bind to an
AT-rich, but not GC-rich, DNA minor groove (Figure 5B).
It is possible that the electron density of an AT-rich DNA
minor groove is more compatible with 1. This prediction
was also consistent with our finding that the addition of
poly (AT) to 1 caused hyperchromicity at longer
Chemistry & Biology
1322wavelengths, but loss of the hypochromicity effect at
short wavelengths (data not shown). Therefore, whether
1 binds to DNA like a nonclassical DNA intercalator or
like a DNA minor groove binder may be influenced by
the sequence of the DNA binding motif. On the other
hand, since 1 is such a small molecule, it is also possible
that it fits into the DNA major groove. We therefore per-
formed another docking experiment that showed that
the resulting 1-DNA complex in the major groove was
less stable than that in the minor groove. The docking
energy was higher than that of the minor groove binding
and intercalation (Table 1).
Compared to 1, analogs 2 and 3 (Figure 1) did not ex-
hibit any DNA binding activities in our experiments (Fig-
ure 4 and data not shown). Molecular simulation studies
revealed that neither 2 nor 3 are able to form an energet-
ically favorable DNA complex, suggesting that the 1-sub-
stitution on 3,4-dihydro b-carboline and the N-alkyl side
chain on carbazole is important for stable DNA binding.
DNA intercalators and minor groove binders such as
simple b-carboline alkaloids, quinacrine, benzimidazole,
and distamycin are known to inhibit DNA topoisomerase
activity [24, 33–35]. 1 also inhibited topo II-mediated
DNA relaxation in vitro. Topo II is a known key enzyme
involved in DNA decatenation, which has to be com-
pleted before cells exit from mitosis. Interference with
the function of topo II, such as that seen with topo II in-
hibitor ICRF-193, can delay cell exit from mitosis and
cause chromosome missegregation [36, 37]. However,
the concentration that is required for 1 to inhibit topo II
was above 50 mM; whether 1-induced aberrant mitosis
relates to the inhibition of topo II requires further studies.
Moreover, 1 does not inhibit topo I (data not shown), in-
dicating that 1 does not inhibit DNA replication.
Our study demonstrates that 1 is a noncovalent DNA
binder that intercalates and binds DNA in the minor
groove. The binding of 1 to chromosome DNA does
not inhibit S phase progression [18], indicating that
DNA binding alone is not sufficient to inhibit DNA repli-
cation or induce DNA damage (responses). Indeed, we
did not observe any activation of DNA damage stress re-
sponses such as those involving p53, p38, and MAPK af-
ter treatment with 1 (data not shown). However, nonco-
valent DNA binding can alter the topology of DNA [12]. It
is possible that the alteration of DNA structure after bind-
ing of 1 to DNA affects chromosome alignment and seg-
regation in mitosis. Elucidation of the mechanisms by
which 1 alter DNA structure requires further study.
Significance
b-Carbolines are known noncovalent DNAbinders, but
the biological effects of this binding are not well un-
derstood. Herein, we identified DNA as amolecular tar-
get by which Mana-Hox induces aberrant mitosis. To
our knowledge, Mana-Hox is the first DNA binder that
does not impede the function of DNA, but impairs
chromosome segregation in mitosis. Since Mana-
Hox exhibits anticancer activity, but is not toxic to nor-
mal cells, the molecular mechanisms by which Mana-
Hox executes its anticancer activity could provide
amodel for future development of b-carboline analogs
as anticancer agents.Experimental Procedures
Reagents and Cell Culture
Compounds 1, 2, and 3 were dissolved in absolute ethanol (Merck).
Paclitaxel and Hoechst 33258 were obtained from Sigma Chemical
Co. (St. Louis, MO, USA) and were dissolved in absolute ethanol
and distilled water, respectively. Etoposide was purchased from
Calbiochem Co. (San Diego, CA, USA) and was dissolved in absolute
ethanol. Calf thymus DNA and topoisomerase II were purchased
from GE healthcare. Streptomycin, penicillin, fetal bovine serum,
L-glutamine, nonessential amino acids, and DMEM were obtained
from Invitrogen (Grand Island, NY, USA).
HeLa cells were obtained from American Type Culture Collection
(ATCC) and were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) medium supplemented with 10% fetal bovine serum,
100 U/ml penicillin, 100 mg/ml streptomycin, 100 mg/ml L-glutamine,
and 100 mg/ml nonessential amino acids.
Intracellular Mana-Hox Localization
HeLa cells were seeded on a coverslip, which was precoated with fe-
tal bovine serum for 30 min prior to cell seeding. Cells were treated
with 4 mM 1 for the indicated time, the coverslip was washed with
PBS, and the cells were observed with a fluorescence microscope
(IX71, Olympus, Tokyo, Japan) under UV excitation (l = 365 nm gen-
erated by mercury arc). For the colocalization studies, HeLa cells
were transfected with pEYFP-Golgi, pEYFP-ER, or pEYFP-Mito-
chondria vectors (Clontech) according to the standard protocols
(GeneJuice, by Novagen). A total of 12 hr posttransfection, cells
were treated with 4 mM Mana-Hox for the indicated time and were
observed with fluorescence microscopy.
Fluorescence Emission Spectrum Measurement
1 at 1 mM was incubated with various concentrations of calf thymus
DNA in 0.01 M ionic strength STE buffer (9.4 mM NaCl, 2 mM Tris-HCl
[pH 7.0], 20 mM EDTA) [38]. Drug solutions with or without calf thy-
mus DNA were excited at 287, 350, or 414 nm, and emission spectra
were recorded with a F4500 spectrophotometer (Hitachi, Japan).
DNA Dye Displacement Assays
For ethidium bromide displacement [39], 20 mM calf thymus DNA
was preincubated with 2 mM ethidium bromide in 0.01 M ionic
strength STE buffer, and was then incubated with 1, 2, and 3 in var-
ious concentrations for another 10 min. The samples were excited at
538 nm, and the fluorescence was measured at 590 nm with a fluo-
rometer (Fluoroskan Ascent, Labsystems, Japan). For the Hoechst
displacement assay [40], 1 mg calf thymus DNA was preincubated
with 6.1 mM Hoechst 33258 in PBS for 10 min at room temperature,
and was then incubated with 1, 2, and 3 in various concentrations for
another 10 min. The samples were excited at 355 nm, and the fluo-
rescence was measured at 460 nm. C50 is the concentration of
DNA binding agent needed to reduce the fluorescence of dye DNA
by 50%. The fluorescence of 1 alone is undetectable in both cases.
Gel Mobility Shift Assay
Supercoiled plasmid pC86 [41] or a 1 kb DNA ladder (2 mg) was pre-
incubated with 10 mM ethidium bromide or various concentrations of
1 for 30 min at room temperature, followed by the addition of 1/6 vol-
ume 63 loading buffer (0.25% bromophenol blue, 0.25% xylene cy-
anol, 50% glycerol) and electrophoresis through a 1.5% agarose gel
at 90 V for 2 hr in 0.53 Tris-borate-EDTA buffer at room temperature
[42]. Next, the gels were stained with ethidium bromide, destained,
and then photographed under UV illumination.
Molecular Modeling
The 3D structures of 1, 2, and 3 were generated by using SYBYL 7.0
(Tripos Associates; St. Louis, MO, USA) and were optimized with the
Tripos force field. The partial atomic charges were calculated by us-
ing the Gasteiger-Marsili method. The flexible torsions for 1were de-
fined with AutoTors implemented in the AutoDock 3.0 software
package (The Scripps Research Institute; La Jolla, CA) [22, 23]. In re-
gard to intercalation modeling, a B form duplex DNA model with the
sequence 50-d(CCGGCGGT)-30 was built by using the BIOPOLYMER/
BUILD module in SYBYL. Hydrogen atoms were added, and Kollman
All-Atom charges were assigned to the DNA molecule. For the
Mana-Hox Binds to DNA
1323generation of an intercalation cavity, 1 was manually docked into
DNA, where the carboline ring was positioned between two base
pairs (CC j GGCGGT), while the carbazole ring was located in the mi-
nor groove. This initial complex structure was then optimized by en-
ergy minimization with the Tripos force field, employing the Powell
method with an energy-gradient-convergence criterion of 0.05 kcal/
(mol$A˚) and a distance-dependent dielectric constant of 4r. 1 and
nonpolar hydrogens were removed from the energy-minimized com-
plex, and the residual DNA was assigned with Kollman United-Atom
charges. The resulting DNA structure with an intercalation cavity
was used in the docking study of 1 with the AutoDock program.
To carry out AutoDock simulations, a grid box was defined to en-
close the intercalation cavity with dimensions of 18.83 18.83 18.8 A˚
and a grid spacing of 0.375 A˚. The grid maps for energy scoring were
calculated by using AutoGrid. Docking was performed by using the
Lamarckian genetic algorithm (LGA) and the pseudo-Solis and Wets
local search method. Default parameters were used, except for en-
ergy evaluations (5 3 105) and docking runs (100). The obtained
ligand-DNA complex structure with the lowest docking energy was
then subjected to energy minimization in SYBYL. The minimization
was first performed as described above, and then the resulting
structure was solvated with a monolayer of water molecules for fur-
ther computation. The solvated system was minimized by fixing the
DNA and ligand molecules, followed by relaxing the entire system.
The two-step solvation calculations were carried out by using an
energy-gradient-convergence criterion of 0.05 kcal/(mol$A˚) and a
dielectric constant of 1.
For modeling on minor groove binding, the X-ray crystal structure
of DNA dodecamer d(CGCAAATTTGCG)2 complexed with Hoechst
33258 (PDB code 264D) was used to prepare the target site for dock-
ing calculations. The ligand and water molecules were removed, and
then polar hydrogens and Kollman United-Atom charges were
added to the DNA. This DNA structure was used for the docking
study in the minor groove region. A grid box was set to enclose
the binding site of Hoechst 33258 with dimensions of 22.5 3
22.53 22.5 A˚ and a grid spacing of 0.375 A˚. Docking was performed
by using the same algorithms and parameters as mentioned above.
The best-scoring docked model was energy minimized by employ-
ing the Powell method with an energy-gradient-convergence crite-
rion of 0.1 kcal/(mol$A˚) and a distance-dependent dielectric con-
stant of 4r. The resulting structure was then solvated with a
monolayer of water molecules, and the energy was minimized by re-
laxing the entire system by using an energy-gradient-convergence
criterion of 0.1 kcal/(mol$A˚) and a dielectric constant of 1. In the
present study, computer simulations were performed on Octane
and Origin 3800 Silicon Graphics workstations.
DNA Relaxation with Topoisomerase II
Topo II reactions were performed in the reaction buffer (50 mM Tris-
HCl [pH 8.0], 120 mM KCl, 10 mM MgCl2, 0.5 mM ATP, 0.5 mM dithio-
threitol, 30 mM bovine serum albumin). Plasmid DNA pC86 (1 mg)
was incubated with various concentrations of 1, and was then
treated with 8 U topoisomerase II for 30 min at 37ºC. The reaction
was stopped by the addition of stop solution (77 mM EDTA, 0.77%
SDS) and 1/6 volume 63 loading buffer [43]. The samples were
electrophoresed through 1% agarose gel at 60 V for 12 hr in 0.53
Tris-borate-EDTA buffer at room temperature. Next, the gels were
stained with ethidium bromide, destained, and then photographed
under UV illumination.
Supplemental Data
Supplemental Data include three figures and can be found at http://
www.chembiol.com/cgi/content/full/12/12/1317/DC1/.
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